This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Pharmacokinetic Study: Effect of 25(OH)D and Vitamin D3 on Serum 25(OH)D

This study has been completed.
Information provided by (Responsible Party):
University of Zurich Identifier:
First received: July 17, 2008
Last updated: December 22, 2011
Last verified: December 2011

We compare the effect of HyD (25-hydroxyvitamin D) and vitamin D3 in their effect on 25-hydroxyvitamin D plasma levels over a course of 4 month. This is a pharmacokinetic study including 35 postmenopausal women.

  • Trial with medicinal product

Condition Intervention Phase
Healthy Drug: 25(OH)D Dietary Supplement: vitamin D3 Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Pharmacokinetic Study in Healthy Postmenopausal Women to Compare Supplementation of Vitamin D3 to 25(OH)D

Resource links provided by NLM:

Further study details as provided by University of Zurich:

Primary Outcome Measures:
  • serum 25(OH)D levels [ Time Frame: repeated assessments over 4 months ]

Secondary Outcome Measures:
  • muscle strength, blood pressure, blood glucose, bone markers [ Time Frame: repeated assessments over 4 months ]

Enrollment: 35
Study Start Date: March 2008
Study Completion Date: September 2008
Primary Completion Date: August 2008 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: 1
Drug: 25(OH)D
daily (20ug), weekly (140 ug), Bolus (140 ug)
Other Name: HyD
Active Comparator: 2
vitamin D3
Dietary Supplement: vitamin D3
daily (800 IU), weekly (5600 IU), Bolus (5600 Iu)
Other Name: Cholecalciferol

Detailed Description:

We include postmenopausal women age 50 to 75, race/ethnicity: Caucasian, serum 25(OH)D at baseline between 20 to 60 nmol/l, body mass index: < 30 kg/m2

to compare 25(OH)D and vitamin D3 in equimolar doses over a 4 month pharmacokinetic trial. The dosing arms are daily, weekly, and bolus


Ages Eligible for Study:   50 Years to 75 Years   (Adult, Senior)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   Yes

Inclusion criteria:

  • Postmenopausal women
  • Age 50 to 75 years
  • Body mass index 18-29 kg/m2
  • 25-hydroxyvitamin D levels 20 to 60 nmol/l
  • Caucasian
  • Generally healthy

Exclusion criteria:

  • Serum calcium > 2.6 nmol/L
  • Use if dietary supplements (> 400 IU vitamin D per day, > 600 mg of calcium per day)
  • Hypertension
  • Diseases that carry the risk of hypercalcemia
  • Use of any drug that interferes with bone metabolism in the last 12 months (bisphosphonates estrogen receptor modulators, PTH, calcitonin)
  • Oral HRT in the last 6 months
  • Extreme diets
  • Fracture or fall in the last 3 months
  • Current smoking or alcohol abuse
  • Planning on a sunny vacation in the course of the trial
  • Kidney stone history
  • Creatinine clearance < 30 ml/min
  • Co-medications: anticoagulants, PTH, corticosteroids, thiazide diuretics, digoxin, anticonvulsants, malabsorption,z C
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00718276

University Hospital Zurich, Centre on Aging and Mobility
Zurich, ZH, Switzerland, 8091
Sponsors and Collaborators
University of Zurich
Principal Investigator: Heike Bischoff Ferrari, MD, MPH University Hospital Zurich, Centre on Aging and Mobility
  More Information

Responsible Party: University of Zurich Identifier: NCT00718276     History of Changes
Other Study ID Numbers: 2007-09-13-HyD
Study First Received: July 17, 2008
Last Updated: December 22, 2011

Keywords provided by University of Zurich:
Healthy postmenopausal women

Additional relevant MeSH terms:
Vitamin D
Growth Substances
Physiological Effects of Drugs
Bone Density Conservation Agents processed this record on August 18, 2017